Drug Profile
Research programme: adenosine A2a receptor agonists - AnaMar
Alternative Names: AM230; AM230 DAR; DARLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator AnaMar AB
- Class Small molecules
- Mechanism of Action Adenosine A2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Rheumatoid-arthritis in Sweden
- 01 Mar 2011 Early research in Rheumatoid arthritis in Sweden (unspecified route)